Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716077 · ClinicalTrials.gov registry record · NA
Early FDG PET in Melanoma
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02716077: Clinical Trial NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02716077 is a NA study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02716077, a NA study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.
Interventions
- RADIATION FDG PET/CT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-03 |
| Phase | NA |
Why NCT02716077 stopped before completion
NCT02716077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which FDG PET/CT imaging is the first listed.
NCT02716077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02716077 about?
NCT02716077 is a clinical study titled "Early FDG PET in Melanoma". Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.
What is the current status of trial NCT02716077?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2016-03. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02716077?
The interventions under investigation include: FDG PET/CT imaging (RADIATION).
Who is sponsoring clinical trial NCT02716077?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02716077's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia